Furthermore, the activity and expression of SPHK-1 are significantly induced under hypoxia and by HIF-1α, and thus is a critical therapeutic target through pVHL-dependent proteasomal degradation for cancer treatment [23, 47–49]. The gene discussed is HIF1A; the disease is cancer.